Abstract:Background: Excessive inflammation results in severe tissue damage as well as serious acute or chronic disorders, and extensive research has focused on finding new anti-inflammatory hit compounds with safety and efficacy profiles from natural products. As promising therapeutic entities for the treatment of inflammation-related diseases, fusaproliferin and its analogs have attracted great interest. However, the underlying anti-inflammatory mechanism is still poorly understood and deserves to be further investigated. Methods: For the estimation of the anti-inflammatory activity of fusaproliferin (1) and its analogs (2-4) in vitro and in vivo, lipopolysaccharide (LPS)-induced RAW264.7 macrophages and zebrafish embryos were employed. Then, transcriptome analysis was applied to guide subsequent western blot analysis of critical proteins in related signaling pathways. Surface plasmon resonance assays (SPR) combined with molecular docking analyses were finally applied to evaluate the affinity interactions between 1-4 and TLR4 and provide a possible interpretation of the downregulation of related signaling pathways. Results: 1-4 significantly attenuated the production of inflammatory messengers, including nitric oxide (NO), reactive oxygen species (ROS), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-alpha), and interleukin-1 beta (IL-1 beta), as well as nitric oxide synthase (iNOS) andcyclooxygenase2 (COX-2), in LPS-induced RAW264.7 macrophages. Transcriptome analyses based on RNA-seq indicated the ability of compound 1 to reverse LPS stimulation and the nuclear factor kappa-B (NF-kappa B) and mitogen-activated protein kinase (MAPKs) signaling pathways contribute to the anti-inflammatory process. Experimental verification at the protein level revealed that 1 can inhibit the activation of inhibitor of NF-kappa B kinase (IKK), degradation of inhibitor of NF-kappa B (I.B), and phosphorylation of NF-kappa B and reduce nuclear translocation of NF kappa B. 1 also decreased the phosphorylation of MAPKs, including p38, extracellular regulated protein kinases (ERK), and c-Jun N-terminal kinase (JNK). SPR assays andmolecular docking results indicated that 1-4 exhibited affinity for the TLR4 protein with KD values of 23.5-29.3 mu M. Conclusion: Fusaproliferin and its analogs can be hit compounds for the treatment of inflammation-associated diseases.

Plasmalogenic Lipid Analogs as Platelet-Activating Factor Antagonists: A Potential Novel Class of Anti-inflammatory Compounds

Lysophospholipid Receptors, As Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation-Novel Paradigm and Therapeutic Potential

Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients

Modulation of Phospholipase A 2 Membrane Activity by Anti-inflammatory Drugs

Critical role of peroxisome proliferator-activated receptor a in promoting platelet hyperreactivity and thrombosis under hyperlipidemia

Advances in the Biosynthetic Pathways and Application Potential of Plasmalogens in Medicine

Investigation of the Anti-Inflammatory Activity of Fusaproliferin Analogues Guided by Transcriptome Analysis

Lipid Mediators in Health and Disease: Enzymes and Receptors as Therapeutic Targets for the Regulation of Immunity and Inflammation

Modified phospholipids as anti-inflammatory compounds

Plasmalogens in Innate Immune Cells: From Arachidonate Signaling to Ferroptosis

Lipoprotein‐associated phospholipase A2: The story continues

Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases

Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease

Lysophospholipids and Their Receptors Serve As Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury.

Lipid biology of plasmalogen-derived halolipids: Signature molecules of myeloperoxidase and eosinophil peroxidase activity

Lipoxin A4 analogue, BML-111, reduces platelet activation and protects from thrombosis

Lipid and Transcriptional Regulation in a Parkinson's Disease Mouse Model by Intranasal Vesicular and Hexosomal Plasmalogen‐based Nanomedicines

Identification of a Novel Series of Anti-Inflammatory and Anti-Oxidative Phospholipid Oxidation Products Containing the Cyclopentenone Moiety in Vitro and in Vivo: Implication in Atherosclerosis

Resveratrol, Tyrosol and Their Derivatives Inhibit Platelet Activating Factor Biosynthetic Enzymes in Homogenized U-937 Cells

Lipid mediators in the regulation of endothelial barriers

Platelet-activating factor (PAF)-antagonists of natural origin